Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03625323 · ClinicalTrials.gov registry record · Phase 2
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
A Phase 2 study, sponsored by Immutep S.A.S..
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT03625323 is a Phase 2 study that has completed, run by Immutep S.A.S.. The registered enrollment target is 187 participants.
The verdict
NCT03625323, a Phase 2 study, has completed, sponsored by Immutep S.A.S..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
Interventions
- DRUG pembrolizumab (KEYTRUDA®)
- DRUG eftilagimod alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2024-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03625323
The ClinicalTrials.gov registry entry for NCT03625323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immutep S.A.S., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab (KEYTRUDA®) is the first listed.
NCT03625323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03625323 about?
NCT03625323 is a clinical study titled "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC". Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
What is the current status of trial NCT03625323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2019-02-21. Estimated completion is 2024-11-25.
What interventions are being tested in trial NCT03625323?
The interventions under investigation include: pembrolizumab (KEYTRUDA®) (DRUG), eftilagimod alpha (DRUG).
Who is sponsoring clinical trial NCT03625323?
This trial is sponsored by Immutep S.A.S., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.